A Study of Pre-Operative Cyberknife in Patients With Potentially Resectable Pancreas Cancer

Inclusion Criteria: * Pathologically confirmed adenocarcinoma of the pancreas * Resectable or potentially resectable disease based on the following imaging criteria performed \< 4 weeks from study entry and as determined by local review (Cooper radiologist) * No extrapancreatic extension to nearby organs (ie; small bowel) * No SMV/PV \>180 degree involvement and/or reconstructable (as determined by Surgeon) occlusion * No SMA Abutment TVI\<180 degrees * No Celiac trunk abutment Total volume involved \< 180 degrees * Note that both resectable and potentially resectable patients are eligible * ECOG ≤ 2 * Adequate hematologic and end organ function as defined by * Hepatic transaminase levels \< 3 x normal * Total bilirubin \< 5 mg/dl (if stented) * Serum creatinine level \< 1.6 mg/dl * Absolute neutrophil count \> 1,500cells/mm3 * Platelet count \> 100,000 cells/mm3 * Medical status suitable for consideration of major pancreatic surgery * Age \>18 years * Women of childbearing age and male participants must practice adequate contraception (hormonal or barrier method of birth control; abstinence) prior to and throughout study treatment. * Life expectancy \> 3 months * Ability to understand and the willingness to sign a written informed consent. Exclusion Criteria: * Prior invasive malignancy within 5 years other than pancreatic adenocarcinoma * Prior radiotherapy to the upper abdomen * Severe comorbidity rendering a candidate ineligible for surgical resection * Local, regional or distant extrapancreatic disease * Patients of childbearing age who are unwilling or unable to practice contraception * Failure to meet any of the above eligibility criteria * Inability to undergo MRI with contrast for treatment planning * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * Patients may not be receiving any other investigational nor commercial agents with therapeutic intent to treat pancreatic cancer while on this trial. * unresectable pancreatic cancer based on the following imaging criteria performed \< 4 weeks from study entry and as determined by local review (Cooper radiologist) * Extrapancreatic extension to nearby organs (ie; small bowel) * SMV/PV \>180 degree involvement and/or reconstructable (as determined by Surgeon) occlusion * SMA Abutment TVI\<180 degrees * Celiac trunk abutment Total volume involved \< 180 degrees * Distant metastases